Clinical Report: Comparison of Electronic Nose and Gas Chromatography-Mass Spectrometry for the Diagnostic Differentiation of Advanced Hepatocellular Carcinoma through Volatolomic Analysis

Overview

This study evaluates the diagnostic performance of electronic nose (eNose) technology compared to gas chromatography-mass spectrometry (GC-MS) for differentiating advanced hepatocellular carcinoma (HCC) from healthy controls. The findings suggest that volatolomic analysis may enhance early detection strategies for HCC.

Background

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with early detection being crucial for improving patient outcomes. Current diagnostic methods primarily rely on imaging and serum biomarkers, which may not be sufficient for early-stage disease. The exploration of volatile organic compounds (VOCs) as non-invasive biomarkers presents a promising avenue for enhancing diagnostic accuracy in HCC.

Data Highlights

This study included 110 participants and compared the diagnostic capabilities of eNose and GC-MS in detecting advanced HCC through volatolomic analysis of blood and urine samples.

Key Findings

• eNose technology demonstrated comparable diagnostic performance to GC-MS in identifying advanced HCC.
• Volatile organic compounds (VOCs) specific to HCC were detected in the breath and biological samples of patients.
• Halogenated and aromatic VOCs were identified as key markers associated with hepatocarcinogenesis.
• The study highlights the potential of non-invasive methods for early detection of HCC.
• Further research is needed to establish the specificity of VOC patterns in HCC compared to other liver diseases.

Clinical Implications

The findings suggest that eNose technology could serve as a valuable adjunct to current diagnostic methods for HCC, potentially improving early detection rates. Clinicians should consider incorporating volatolomic analysis into their diagnostic protocols, especially for high-risk populations.

Conclusion

The study supports the use of eNose technology as a promising tool for the non-invasive diagnosis of advanced HCC. Continued research is essential to validate these findings and integrate them into clinical practice.

Related Resources & Content

1. Exploratory Study on Bladder Cancer Identification Through Volatile Organic Compounds and Ion Mobility Spectrometry: An Innovative Urine-Based Method, Springer, 2024 -- https://link.springer.com/article/10.1007/s00345-024-05047-5
2. Utilizing Metabolic Profiling to Investigate Cellular Changes Induced by 20 Mycotoxins in HepG2 Cell Lines, Archives of Toxicology, 2022 -- https://link.springer.com/article/10.1007/s00204-022-03348-5
3. Gastric Cancer Detected in a Breath Test, The ASCO Post, 2014 -- https://ascopost.com/issues/june-25-2014/gastric-cancer-detected-in-a-breath-test/
4. EASL Management of Hepatocellular Carcinoma Guideline Summary, Guideline Central, 2025 -- https://www.guidelinecentral.com/guideline/4543028/?utm_source=openai
5. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis, ScienceDirect, 2025 -- https://www.sciencedirect.com/science/article/pii/S001650852405460X?utm_source=openai
6. npj Digital Medicine — Hierarchical Deep Convolutional Neural Networks for Enhanced Breath Analysis in Multi-Cancer Detection
7. EASL Management of Hepatocellular Carcinoma Guideline Summary - Guideline Central
8. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis - ScienceDirect
9. Diagnostic accuracy of breath tests based on volatile organic compounds for cancer: A systematic review and meta-analysis - ScienceDirect